Please use this identifier to cite or link to this item:
|Title:||Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.|
|Authors:||Lau, David K;Tay, Rebecca Y;Yeung, Yvonne H;Chionh, Fiona;Mooi, Jennifer;Murone, Carmel;Skrinos, Effie;Price, Timothy J;Mariadason, John M;Tebbutt, Niall C|
|Affiliation:||Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia|
School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia
Dept of Medical Oncology, Olivia Newton John Cancer Wellness & Research Centre, Austin Health, Heidelberg, Victoria, Australia
The Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia
|Citation:||British journal of cancer 2018; 118(7): 966-971|
|Abstract:||Advanced biliary tract cancers (BTCs) have a poor prognosis and limited treatment options. This exploratory phase II study aimed to evaluate the activity of the mTOR inhibitor everolimus in advanced BTC and explore prognostic biomarkers. Patients with advanced BTCs, who had not received chemotherapy for advanced disease, were enroled to receive everolimus (10 mg daily). The primary endpoint was disease control rate (DCR) at 12 weeks. Secondary endpoints included overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events. Activation status of the RAS and phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathways was assessed by DNA sequencing and immunohistochemistry on archival tumour tissue. The study enroled 27 patients and the DCR at 12 weeks was 48%. Median PFS was 5.5 months (95% confidence interval (CI): 2.1-10.0 months) and median OS was 9.5 months (95% CI: 5.5-16.6 months). DCR at 12 weeks was significantly worse for gall bladder carcinoma compared to other anatomical sites, and there was a trend towards a worsened PFS and OS. Treatment was well tolerated. KRAS (12%) and PIK3CA mutations (12%) were uncommon. Immunohistochemical staining for PI3K/AKT/mTOR pathways did not significantly correlate with outcome. In unselected patients, everolimus demonstrated clinical activity as first-line monotherapy in advanced BTC.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.